フォーミュレーション開発アウトソーシング市場シェア2025-2035

---

Table of Contents

1. Methodology & Report Coverage

1.1. Definition & Objective

1.2. Market Evaluation & forecast parameter

1.3. Research Methodology

1.4. Data Validation Sources

1.4.1. Secondary Research

1.4.2. Primary Research

2. Market Overview

3. Formulation Development Outsourcing Market: Market Dynamics

3.1. Executive Summary

3.2. Market Driving Factors

3.2.1. Rising R&D costs push companies to outsource formulation to cut internal expenses.

3.2.2. Growth in biologics and complex drug delivery systems demands specialized formulation expertise.

3.2.3. Faster time-to-market needs drive adoption of external formulation development services.

3.3. Key industry pitfalls & challenges

3.3.1. Data security concerns and IP risks deter full reliance on external development partners.

3.3.2. Limited standardization in formulation processes across CROs impacts quality and consistency.

3.3.3. High initial outsourcing costs may deter small or emerging pharmaceutical companies.

3.4. Market Opportunities

3.4.1. Expansion of personalized medicine creates demand for tailored drug formulation services.

3.4.2. Emerging markets offer growth for CROs due to lower costs and skilled workforce.

3.4.3. Advancements in AI-driven formulation tools enhance outsourcing service efficiency and accuracy.

3.5. Porter’s Five Forces Analysis

3.6. PESTLE Analysis

3.7. Regulatory landscape

3.8. Investment Landscape

3.9. ESG Scenario

3.10. Competitive landscape

3.10.1. Company Market Share

3.10.2. Market Positioning

3.10.3. Strategy framework

3.10.4. Recent Acquisitions & Mergers

4. Formulation Development Outsourcing Market, Service Type Segment Analysis

4.1. Overview Dynamics

4.1.1. Market Revenue Share, By Service Type, 2025 & 2035

4.1.2. Key Market Trends, Growth Factors, & Opportunities

4.2. Pre-formulation Services

4.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.2.2. API characterization

4.2.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.2.3. Excipient compatibility studies

4.2.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.2.4. Physicochemical property analysis

4.2.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.3. Formulation Development Services

4.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.3.2. Oral formulations

4.3.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.3.3. Parenteral formulations

4.3.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.3.4. Topical formulations

4.3.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.3.5. Inhaled and nasal formulations

4.3.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.3.6. Ophthalmic formulations

4.3.6.1. Market Size and Forecast, 2025-2035 (USD Billion)

5. Formulation Development Outsourcing Market, Formulation Type Segment Analysis

5.1. Overview

5.1.1. Market Revenue Share, By Formulation Type, 2025 & 2035

5.1.2. Key Market Trends, Growth Factors, & Opportunities

5.2. Small Molecule Drugs

5.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.3. Large Molecule

5.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.4. Controlled Release Formulations

5.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.5. Immediate Release Formulations

5.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.6. Modified Release Formulations

5.6.1. Market Size and Forecast, 2025-2035 (USD Billion)

6. Formulation Development Outsourcing Market, Therapeutic Area Segment Analysis

6.1. Overview

6.1.1. Market Revenue Share, By Therapeutic Area, 2025 & 2035

6.1.2. Key Market Trends, Growth Factors, & Opportunities

6.2. Oncology

6.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.3. Cardiovascular Diseases

6.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.4. Infectious Diseases

6.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.5. Neurology

6.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.6. Diabetes

6.6.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.7. Respiratory Disorders

6.7.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.8. Others

6.8.1. Market Size and Forecast, 2025-2035 (USD Billion)

7. Formulation Development Outsourcing Market, End-user Segment Analysis

7.1. Overview

7.1.1. Market Revenue Share, By End-user, 2025 & 2035

7.1.2. Key Market Trends, Growth Factors, & Opportunities

7.2. Pharmaceutical Companies

7.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.3. Biotechnology Companies

7.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.4. Academic and Research Institutions

7.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.5. Contract Manufacturing Organizations

7.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

8. Formulation Development Outsourcing Market, Region Segment Analysis

8.1. Overview

8.1.1. Global Market Revenue Share, By Region, 2025 & 2035

8.1.2. Global Market Revenue, By Region, 2025-2035(USD Billion)

8.2. North America

8.2.1. North America Market Revenue, By Country, 2025-2035(USD Billion)

8.2.2. North America Market Revenue, By Service Type, 2025-2035

8.2.3. North America Market Revenue, By Formulation Type, 2025-2035

8.2.4. North America Market Revenue, By Therapeutic Area, 2025-2035

8.2.5. North America Market Revenue, By End-user, 2025-2035

8.2.6. The U.S.

8.2.6.1. U.S. Market Revenue, By Service Type, 2025-2035

8.2.6.2. U.S. Market Revenue, By Formulation Type, 2025-2035

8.2.6.3. U.S. Market Revenue, By Therapeutic Area, 2025-2035

8.2.6.4. U.S. Market Revenue, By End-user, 2025-2035

8.2.7. Canada

8.2.7.1. Canada Market Revenue, By Service Type, 2025-2035

8.2.7.2. Canada Market Revenue, By Formulation Type, 2025-2035

8.2.7.3. Canada Market Revenue, By Therapeutic Area, 2025-2035

8.2.7.4. Canada Market Revenue, By End-user, 2025-2035

8.3. Europe

8.3.1. Europe Market Revenue, By Country, 2025-2035(USD Billion)

8.3.2. Europe Market Revenue, By Service Type, 2025-2035

8.3.3. Europe Market Revenue, By Formulation Type, 2025-2035

8.3.4. Europe Market Revenue, By Therapeutic Area, 2025-2035

8.3.5. Europe Market Revenue, By End-user, 2025-2035

8.3.6. Germany

8.3.6.1. Germany Market Revenue, By Service Type, 2025-2035

8.3.6.2. Germany Market Revenue, By Formulation Type, 2025-2035

8.3.6.3. Germany Market Revenue, By Therapeutic Area, 2025-2035

8.3.6.4. Germany Market Revenue, By End-user, 2025-2035

8.3.7. France

8.3.7.1. France Market Revenue, By Service Type, 2025-2035

8.3.7.2. France Market Revenue, By Formulation Type, 2025-2035

8.3.7.3. France Market Revenue, By Therapeutic Area, 2025-2035

8.3.7.4. France Market Revenue, By End-user, 2025-2035

8.3.8. U.K.

8.3.8.1. U.K. Market Revenue, By Service Type, 2025-2035

8.3.8.2. U.K. Market Revenue, By Formulation Type, 2025-2035

8.3.8.3. U.K. Market Revenue, By Therapeutic Area, 2025-2035

8.3.8.4. U.K. Market Revenue, By End-user, 2025-2035

8.3.9. Italy

8.3.9.1. Italy Market Revenue, By Service Type, 2025-2035

8.3.9.2. Italy Market Revenue, By Formulation Type, 2025-2035

8.3.9.3. Italy Market Revenue, By Therapeutic Area, 2025-2035

8.3.9.4. Italy Market Revenue, By End-user, 2025-2035

8.3.10. Spain

8.3.10.1. Spain Market Revenue, By Service Type, 2025-2035

8.3.10.2. Spain Market Revenue, By Formulation Type, 2025-2035

8.3.10.3. Spain Market Revenue, By Therapeutic Area, 2025-2035

8.3.10.4. Spain Market Revenue, By End-user, 2025-2035

8.3.11. Rest of Europe

8.3.11.1. Rest of Europe Market Revenue, By Service Type, 2025-2035

8.3.11.2. Rest of Europe Market Revenue, By Formulation Type, 2025-2035

8.3.11.3. Rest of Europe Market Revenue, By Therapeutic Area, 2025-2035

8.3.11.4. Rest of Europe Market Revenue, By End-user, 2025-2035

8.4. Asia Pacific

8.4.1. Asia Pacific Market Revenue, By Country, 2025-2035(USD Billion)

8.4.2. Asia Pacific Market Revenue, By Service Type, 2025-2035

8.4.3. Asia Pacific Market Revenue, By Formulation Type, 2025-2035

8.4.4. Asia Pacific Market Revenue, By Therapeutic Area, 2025-2035

8.4.5. Asia Pacific Market Revenue, By End-user, 2025-2035

8.4.6. China

8.4.6.1. China Market Revenue, By Service Type, 2025-2035

8.4.6.2. China Market Revenue, By Formulation Type, 2025-2035

8.4.6.3. China Market Revenue, By Therapeutic Area, 2025-2035

8.4.6.4. China Market Revenue, By End-user, 2025-2035

8.4.7. Japan

8.4.7.1. Japan Market Revenue, By Service Type, 2025-2035

8.4.7.2. Japan Market Revenue, By Formulation Type, 2025-2035

8.4.7.3. Japan Market Revenue, By Therapeutic Area, 2025-2035

8.4.7.4. Japan Market Revenue, By End-user, 2025-2035

8.4.8. India

8.4.8.1. India Market Revenue, By Service Type, 2025-2035

8.4.8.2. India Market Revenue, By Formulation Type, 2025-2035

8.4.8.3. India Market Revenue, By Therapeutic Area, 2025-2035

8.4.8.4. India Market Revenue, By End-user, 2025-2035

8.4.9. Australia

8.4.9.1. Australia Market Revenue, By Service Type, 2025-2035

8.4.9.2. Australia Market Revenue, By Formulation Type, 2025-2035

8.4.9.3. Australia Market Revenue, By Therapeutic Area, 2025-2035

8.4.9.4. Australia Market Revenue, By End-user, 2025-2035

8.4.10. South Korea

8.4.10.1. South Korea Market Revenue, By Service Type, 2025-2035

8.4.10.2. South Korea Market Revenue, By Formulation Type, 2025-2035

8.4.10.3. South Korea Market Revenue, By Therapeutic Area, 2025-2035

8.4.10.4. South Korea Market Revenue, By End-user, 2025-2035

8.4.11. Singapore

8.4.11.1. Singapore Market Revenue, By Service Type, 2025-2035

8.4.11.2. Singapore Market Revenue, By Formulation Type, 2025-2035

8.4.11.3. Singapore Market Revenue, By Therapeutic Area, 2025-2035

8.4.11.4. Singapore Market Revenue, By End-user, 2025-2035

8.4.12. Rest of Asia Pacific

8.4.12.1. Rest of Asia Pacific Market Revenue, By Service Type, 2025-2035

8.4.12.2. Rest of Asia Pacific Market Revenue, By Formulation Type, 2025-2035

8.4.12.3. Rest of Asia Pacific Market Revenue, By Therapeutic Area, 2025-2035

8.4.12.4. Rest of Asia Pacific Market Revenue, By End-user, 2025-2035

8.5. Latin America

8.5.1. Latin America Market Revenue, By Country, 2025-2035(USD Billion)

8.5.2. Latin America Market Revenue, By Service Type, 2025-2035

8.5.3. Latin America Market Revenue, By Formulation Type, 2025-2035

8.5.4. Latin America Market Revenue, By Therapeutic Area, 2025-2035

8.5.5. Latin America Market Revenue, By End-user, 2025-2035

8.5.6. Brazil

8.5.6.1. Brazil Market Revenue, By Service Type, 2025-2035

8.5.6.2. Brazil Market Revenue, By Formulation Type, 2025-2035

8.5.6.3. Brazil Market Revenue, By Therapeutic Area, 2025-2035

8.5.6.4. Brazil Market Revenue, By End-user, 2025-2035

8.5.7. Argentina

8.5.7.1. Argentina Market Revenue, By Service Type, 2025-2035

8.5.7.2. Argentina Market Revenue, By Formulation Type, 2025-2035

8.5.7.3. Argentina Market Revenue, By Therapeutic Area, 2025-2035

8.5.7.4. Argentina Market Revenue, By End-user, 2025-2035

8.5.8. Mexico

8.5.8.1. Mexico Market Revenue, By Service Type, 2025-2035

8.5.8.2. Mexico Market Revenue, By Formulation Type, 2025-2035

8.5.8.3. Mexico Market Revenue, By Therapeutic Area, 2025-2035

8.5.8.4. Mexico Market Revenue, By End-user, 2025-2035

8.5.9. Rest of Latin America

8.5.9.1. Rest of Latin America Market Revenue, By Service Type, 2025-2035

8.5.9.2. Rest of Latin America Market Revenue, By Formulation Type, 2025-2035

8.5.9.3. Rest of Latin America Market Revenue, By Therapeutic Area, 2025-2035

8.5.9.4. Rest of Latin America Market Revenue, By End-user, 2025-2035

8.6. MEA

8.6.1. MEA Market Revenue, By Country, 2025-2035(USD Billion)

8.6.2. MEA Market Revenue, By Service Type, 2025-2035

8.6.3. MEA Market Revenue, By Formulation Type, 2025-2035

8.6.4. MEA Market Revenue, By Therapeutic Area, 2025-2035

8.6.5. MEA Market Revenue, By End-user, 2025-2035

8.6.6. GCC Countries

8.6.6.1. GCC Countries Market Revenue, By Service Type, 2025-2035

8.6.6.2. GCC Countries Market Revenue, By Formulation Type, 2025-2035

8.6.6.3. GCC Countries Market Revenue, By Therapeutic Area, 2025-2035

8.6.6.4. GCC Countries Market Revenue, By End-user, 2025-2035

8.6.7. South Africa

8.6.7.1. South Africa Market Revenue, By Service Type, 2025-2035

8.6.7.2. South Africa Market Revenue, By Formulation Type, 2025-2035

8.6.7.3. South Africa Market Revenue, By Therapeutic Area, 2025-2035

8.6.7.4. South Africa Market Revenue, By End-user, 2025-2035

8.6.8. Rest of Middle East & Africa

8.6.8.1. Rest of Middle East & Africa Market Revenue, By Service Type, 2025-2035

8.6.8.2. Rest of Middle East & Africa Market Revenue, By Formulation Type, 2025-2035

8.6.8.3. Rest of Middle East & Africa Market Revenue, By Therapeutic Area, 2025-2035

8.6.8.4. Rest of Middle East & Africa Market Revenue, By End-user, 2025-2035

9. Company Profile

9.1. Catalent, Inc.

9.1.1. Business Overview

9.1.2. Financial Performance

9.1.3. Product/Service Offerings

9.1.4. Strategies & recent developments

9.1.5. SWOT Analysis

9.2. Lonza Group AG

9.2.1. Business Overview

9.2.2. Financial Performance

9.2.3. Product/Service Offerings

9.2.4. Strategies & recent developments

9.2.5. SWOT Analysis

9.3. Recipharm AB

9.3.1. Business Overview

9.3.2. Financial Performance

9.3.3. Product/Service Offerings

9.3.4. Strategies & recent developments

9.3.5. SWOT Analysis

9.4. Evonik Industries AG

9.4.1. Business Overview

9.4.2. Financial Performance

9.4.3. Product/Service Offerings

9.4.4. Strategies & recent developments

9.4.5. SWOT Analysis

9.5. Thermo Fisher Scientific Inc. (Patheon)

9.5.1. Business Overview

9.5.2. Financial Performance

9.5.3. Product/Service Offerings

9.5.4. Strategies & recent developments

9.5.5. SWOT Analysis

9.6. Siegfried Holding AG

9.6.1. Business Overview

9.6.2. Financial Performance

9.6.3. Product/Service Offerings

9.6.4. Strategies & recent developments

9.6.5. SWOT Analysis

9.7. Cambrex Corporation

9.7.1. Business Overview

9.7.2. Financial Performance

9.7.3. Product/Service Offerings

9.7.4. Strategies & recent developments

9.7.5. SWOT Analysis

9.8. Syngene International Ltd.

9.8.1. Business Overview

9.8.2. Financial Performance

9.8.3. Product/Service Offerings

9.8.4. Strategies & recent developments

9.8.5. SWOT Analysis

9.9. Samsung Biologics

9.9.1. Business Overview

9.9.2. Financial Performance

9.9.3. Product/Service Offerings

9.9.4. Strategies & recent developments

9.9.5. SWOT Analysis

9.10. Baxter BioPharma Solutions

9.10.1. Business Overview

9.10.2. Financial Performance

9.10.3. Product/Service Offerings

9.10.4. Strategies & recent developments

9.10.5. SWOT Analysis

9.11. Ajinomoto Bio-Pharma Services

9.11.1. Business Overview

9.11.2. Financial Performance

9.11.3. Product/Service Offerings

9.11.4. Strategies & recent developments

9.11.5. SWOT Analysis

9.12. Piramal Pharma Solutions

9.12.1. Business Overview

9.12.2. Financial Performance

9.12.3. Product/Service Offerings

9.12.4. Strategies & recent developments

9.12.5. SWOT Analysis

9.13. Adare Pharma Solutions

9.13.1. Business Overview

9.13.2. Financial Performance

9.13.3. Product/Service Offerings

9.13.4. Strategies & recent developments

9.13.5. SWOT Analysis

9.14. Charles River Laboratories

9.14.1. Business Overview

9.14.2. Financial Performance

9.14.3. Product/Service Offerings

9.14.4. Strategies & recent developments

9.14.5. SWOT Analysis

9.15. MedPharm Ltd.

9.15.1. Business Overview

9.15.2. Financial Performance

9.15.3. Product/Service Offerings

9.15.4. Strategies & recent developments

9.15.5. SWOT Analysis